| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/08/2013 | US20130203671 Flibanserin for the Treatment of Urinary Incontinence and Related Diseases |
| 08/08/2013 | US20130203668 Pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent |
| 08/08/2013 | US20130203666 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| 08/08/2013 | US20130203664 Hypocaloric, high protein nutritional compositions and methods of using same |
| 08/08/2013 | US20130203663 Tube feed formulations and methods for using same |
| 08/08/2013 | US20130203658 Low-Caloric High-Protein Nutritional Composition for the Stimulation of Muscle Protein Synthesis |
| 08/08/2013 | US20130203646 Supporting activities of daily living |
| 08/08/2013 | US20130203645 Method of enhancing muscle protein synthesis |
| 08/08/2013 | US20130203619 Methods for Detecting, Diagnosing and Treating Human Renal Cell Carcinoma |
| 08/08/2013 | US20130202725 Method of preparing a muscadine pomace extract |
| 08/08/2013 | US20130202724 Soybean extracts for the treatment of hepatic disorders |
| 08/08/2013 | US20130202722 Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof |
| 08/08/2013 | US20130202719 Stabilized chlorite solutions in combination with fluropyrimidines for cancer |
| 08/08/2013 | US20130202716 Treatment of Cancer Using Hypoxia Activated Prodrugs |
| 08/08/2013 | US20130202712 Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease |
| 08/08/2013 | US20130202709 Methods of treatment of pancreatic cancer |
| 08/08/2013 | US20130202707 Controlled Delivery of TLR Agonists in Structural Polymeric Devices |
| 08/08/2013 | US20130202704 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome |
| 08/08/2013 | US20130202702 Oral formulations |
| 08/08/2013 | US20130202701 (1r,4r)-6'-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for Treating Fibromyalgia and Chronic Fatigue Syndrome |
| 08/08/2013 | US20130202699 Phosphate binder formulation for simple dosing |
| 08/08/2013 | US20130202698 L-ornidazole formulations and their applications in treatment of parasitic infections |
| 08/08/2013 | US20130202693 Oral Dosage Forms of Bendamustine |
| 08/08/2013 | US20130202690 Encapsulated picoplatin |
| 08/08/2013 | US20130202689 Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
| 08/08/2013 | US20130202685 Use of a histamine H4 antagonist for the treatment of post-operative adhesions |
| 08/08/2013 | US20130202681 Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles |
| 08/08/2013 | US20130202680 Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate |
| 08/08/2013 | US20130202679 Targeted Particles Comprising Landscape Phage Fusion Proteins and Heterologous Nucleic Acid |
| 08/08/2013 | US20130202677 Patch |
| 08/08/2013 | US20130202673 Heterogeneous implantable devices for drug delivery |
| 08/08/2013 | US20130202663 Remedy |
| 08/08/2013 | US20130202662 o/w/o EMULSION CONTAINING LIGNAN COMPOUNDS AND COMPOSITION CONTAINING THE SAME |
| 08/08/2013 | US20130202661 Formulations of viloxazine |
| 08/08/2013 | US20130202658 Compositions Comprising Buprenorphine |
| 08/08/2013 | US20130202655 Vaccines, Methods of Administering Vaccines, Methods and Products for Treating and/or Delaying Onset of Dysplastic Lesions, and Wafers for Oral Administration |
| 08/08/2013 | US20130202654 Topical Foam Composition |
| 08/08/2013 | US20130202653 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity |
| 08/08/2013 | US20130202648 Immunoregulator Compounds |
| 08/08/2013 | US20130202637 Dietary Supplements Including Ellagitannins and Ellagic Acid |
| 08/08/2013 | US20130202619 Methods and materials for reducing liver fibrosis |
| 08/08/2013 | US20130202612 Compositions and methods for treating bone conditions |
| 08/08/2013 | US20130202611 Use of inhibitors of bruton's tyrosine kinase (btk) |
| 08/08/2013 | US20130202601 Assays, methods and kits for predicting renal disease and personalized treatment strategies |
| 08/08/2013 | US20130202594 ALK1 Antagonists and Their Uses in Treating Renal Cell Carcinoma |
| 08/08/2013 | US20130202590 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| 08/08/2013 | US20130202588 Antitumor T Cell Response Enhancer |
| 08/08/2013 | US20130202580 Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis |
| 08/08/2013 | US20130202573 Thioacetate compounds, compositions and methods of use |
| 08/08/2013 | US20130202572 Caffeine-free dietary supplements for increasing energy and methods of administering the same |
| 08/08/2013 | US20130202570 Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof |
| 08/08/2013 | US20130202556 Treatment of Hepatitis C Virus Related Diseases Using Hydroxychloroquine or a Combination of Hydroxychloroquine and an Anti-Viral Agent |
| 08/08/2013 | US20130202555 Treatment of multiple sclerosis with masitinib |
| 08/08/2013 | US20130202553 Mobilization of hematopoietic stem cells |
| 08/08/2013 | US20130202550 Non-anticoagulant sulfated or sulfonated synthetic polymers |
| 08/08/2013 | US20130202533 Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination |
| 08/08/2013 | US20130202529 Benztropine compounds and uses thereof |
| 08/08/2013 | US20130199519 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 08/08/2013 | DE202013005992U1 Pharmazeutische Zusammensetzung umfassend Ofloxacin und Cefuroxim A pharmaceutical composition comprising ofloxacin and cefuroxime |
| 08/08/2013 | DE102012020045A1 Chymotrypsin-Lösung Chymotrypsin solution |
| 08/08/2013 | DE102012002372A1 Konzentrat für eine Dialysierflüssigkeit und daraus hergestellte Dialysierflüssigkeit Concentrate for a dialysis fluid and derived dialysis fluid |
| 08/08/2013 | CA2861415A1 Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates |
| 08/08/2013 | CA2861377A1 Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
| 08/08/2013 | CA2857430A1 Wafer and capsule formulations with enhanced dissolution rates for fenofibrate |
| 08/08/2013 | CA2857082A1 Diethyl-[6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)- naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dysttrophy |
| 08/07/2013 | EP2623602A2 Aptamer therapeutics useful in the treatment of complement-related disorders |
| 08/07/2013 | EP2623600A1 Inhibitor of expression of dominantly mutated gene |
| 08/07/2013 | EP2623599A1 Micromirs |
| 08/07/2013 | EP2623598A1 Micromirs |
| 08/07/2013 | EP2623592A1 Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier |
| 08/07/2013 | EP2623510A1 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases |
| 08/07/2013 | EP2623505A1 (aza)indolizine derivative and pharmaceutical use thereof |
| 08/07/2013 | EP2623504A1 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases |
| 08/07/2013 | EP2623503A1 Chromene derivatives |
| 08/07/2013 | EP2623499A1 1,2,4-triazolone derivative |
| 08/07/2013 | EP2623498A1 Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| 08/07/2013 | EP2623497A1 Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| 08/07/2013 | EP2623495A1 Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate |
| 08/07/2013 | EP2623494A1 Agent for treatment of eye diseases |
| 08/07/2013 | EP2623493A1 N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators |
| 08/07/2013 | EP2623492A1 Cyclohexane derivative compound |
| 08/07/2013 | EP2623491A2 Piperidine and piperazine derivatives as autotaxin inhibitors |
| 08/07/2013 | EP2623490A1 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma |
| 08/07/2013 | EP2623120A2 Compositions comprising dietary fat complexer and methods for their use |
| 08/07/2013 | EP2623119A1 Glioma treatment method, glioma examination method, method of delivering a desired material to a glioma, and drug used in said methods |
| 08/07/2013 | EP2623107A1 Arctigenin-containing bardanae fructus extract and method for producing same |
| 08/07/2013 | EP2623105A2 Modulation of line-1 reverse transcriptase |
| 08/07/2013 | EP2623104A1 Substituted nucleoside and nucleotide analogs |
| 08/07/2013 | EP2623103A1 Patch |
| 08/07/2013 | EP2623102A1 Transdermal absorption preparation |
| 08/07/2013 | EP2623101A1 Piperidine and piperazine derivatives as autotaxin inhibitors |
| 08/07/2013 | EP2623100A1 Preparation for improving solubility of poorly soluble drug |
| 08/07/2013 | EP2623099A1 Composition and method for treating neurological disease |
| 08/07/2013 | EP2623098A1 Amide Amino Acid Esters of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) as Potent Inhibitors of Colon Tumor Cell Growth |
| 08/07/2013 | EP2623096A2 Pharmaceutical composition with slow release of trimetazidine |
| 08/07/2013 | EP2623095A1 Injectable nanoparticulate olanzapine formulations |
| 08/07/2013 | EP2622354A1 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
| 08/07/2013 | EP2622076A1 Treatment of b-cell lymphoma with microrna |
| 08/07/2013 | EP2622075A1 Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities |
| 08/07/2013 | EP2621932A1 Tetracyclic heterocycle compounds for treating hepatitis c viral infection |